Key points
- A director at ADARx Pharmaceuticals bought $17.13 million of common stock in a single reported day. George Simeon, listed in the filings as a Director, is the buyer.
- The purchase covered 1,007,407 shares at a flat price of $17.00. Two Form 4 filings carry the transaction date September 28th, 2026.
- The last price on record for ADRX is $19.94. That is above the price Simeon paid on the transaction date.
- ADARx Pharmaceuticals carries a market capitalization of $2,129,618,560. The company is classified under Pharmaceutical Preparations.
George Simeon, a director of ADARx Pharmaceuticals, Inc., reported buying 1,007,407 shares of the company's common stock for a total of $17.13 million. The transactions are dated September 28th, 2026, and reach the public record through two separate Form 4 filings.
Every share in the reported block changed hands at $17.00. There is no spread in the reported price range, which is the signature of a single negotiated or single-fill purchase rather than a series of open market trades worked across a session.
What the filing shows
The buyer is an individual, not an institution, and the role on the filing is Director. The dollar figure, $17.13 million, is the full value of what was reported across both documents for the transaction date of September 28th, 2026.
A flat $17.00 price on 1,007,407 shares is the detail worth holding onto. When an insider accumulates in the open market over hours, the Form 4 usually shows a weighted average or a band of prices. A single clean figure points to one transaction or a set of transactions struck at one agreed level.
What the insider did
Simeon's position change is reported as a purchase, so this is not an option exercise being unwound or a grant settling. The filings put the money in on the buy side at $17.00 per share.
Two filings for one transaction date is common when shares are held through more than one account or entity, or when separate reporting lines are required for direct and indirect holdings. The reconciled total across both is the $17.13 million figure.
Directors sit outside day to day operations but inside the boardroom, which is why Form 4 activity from a board seat gets read differently from activity by an operating officer. The filing itself does not state a reason for the purchase, and nothing beyond the reported transaction should be read into it.
Where the stock sits
ADRX last printed at $19.94. The purchase price on the September 28th, 2026 filings was $17.00, so the market has since traded above the level the director paid.
Market capitalization stands at $2,129,618,560. Against that, a $17.13 million purchase is a modest slice of the company by value, but it is a large single commitment for one person to make in one day.
What that leaves
ADARx Pharmaceuticals operates in Pharmaceutical Preparations, a sector where valuations move on clinical readouts and partnership news rather than on quarterly operating results. Insider purchases in that setting carry the usual caveat: a board member's buy is one data point, and it is a backward looking one by the time it reaches EDGAR.
What is verifiable here is narrow and specific. A director bought 1,007,407 shares at $17.00 on September 28th, 2026, for $17.13 million, reported across two filings, in a company with a market capitalization of $2,129,618,560, and the stock last traded at $19.94.
Anything past that, including motive, timing judgment, or what the board may know, is not in the filing and is not stated here. Readers tracking ADRX should watch for any follow on Form 4 activity from the same filer or from other officers and directors, since a single purchase and a pattern of purchases are different signals.
Sources: SEC Form 4 filings submitted via EDGAR and reviewed by InsiderBuying.com, covering transactions dated September 28th, 2026.
Informational only, not investment advice.